| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.975 auroc unitless · higher Uncertainty: 95% CI 0.9651 to 0.9843 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C17; group 'BRCA'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.947 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9280 to 0.9660 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E17; group 'BRCA'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.885 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8566 to 0.9134 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D17; group 'BRCA'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.977 auroc unitless · higher Uncertainty: 95% CI 0.9706 to 0.9838 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C27; group 'CHOL'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.887 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8492 to 0.9242 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E27; group 'CHOL'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.79 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7408 to 0.8392 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D27; group 'CHOL'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.978 auroc unitless · higher Uncertainty: 95% CI 0.9696 to 0.9860 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C37; group 'CRC'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.908 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8752 to 0.9414 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E37; group 'CRC'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.868 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8310 to 0.9057 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D37; group 'CRC'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024) | 0.943 auroc unitless · higher Uncertainty: 95% CI 0.9315 to 0.9542 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Jiang cohort liver cancer cross-validation ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C87; group 'LIHC'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.997 auroc unitless · higher Uncertainty: 95% CI 0.9936 to 0.9997 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C57; group 'NSCLC'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.975 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9495 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E57; group 'NSCLC'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.965 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9332 to 0.9968 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D57; group 'NSCLC'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.999 auroc unitless · higher Uncertainty: 95% CI 0.9980 to 0.9997 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C67; group 'OV'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E67; group 'OV'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.975 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9569 to 0.9931 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D67; group 'OV'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.838 auroc unitless · higher Uncertainty: 95% CI 0.8051 to 0.8712 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C77; group 'PAAD'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.73 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.6810 to 0.7790 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E77; group 'PAAD'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.566 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.5110 to 0.6207 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D77; group 'PAAD'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.964 auroc unitless · higher Uncertainty: 95% CI 0.9585 to 0.9692 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C7; group 'PANCAN'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.963 auroc unitless · higher Uncertainty: 95% CI 0.9446 to 0.9815 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C47; group 'STAD'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.94 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9110 to 0.9690 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E47; group 'STAD'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.853 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8066 to 0.9001 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D47; group 'STAD'; row 'coverage'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.731 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C17; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'coverage'; column 'AUC' |
|---|
| Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.543 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcecoverage (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E17; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'coverage'; column 'Sensitivity @85% specificity' |
|---|